» Articles » PMID: 26992070

High-sensitivity HLA Class I Peptidome Analysis Enables a Precise Definition of Peptide Motifs and the Identification of Peptides from Cell Lines and Patients' Sera

Overview
Journal Proteomics
Date 2016 Mar 19
PMID 26992070
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The characterization of peptides bound to human leukocyte antigen (HLA) class I is of fundamental importance for understanding CD8+ T cell-driven immunological processes and for the development of immunomodulatory therapeutic strategies. However, until now, the mass spectrometric analysis of HLA-bound peptides has typically required billions of cells, still resulting in relatively few high-confidence peptide identifications. Capitalizing on the recent developments in mass spectrometry and bioinformatics, we have implemented a methodology for the efficient recovery of acid-eluted HLA peptides after purification with the pan-reactive antibody W6/32 and have identified a total of 27 862 unique peptides with high confidence (1% false discovery rate) from five human cancer cell lines. More than 93% of the identified peptides were eight to 11 amino acids in length and contained signatures that were in excellent agreement with published HLA binding motifs. Furthermore, by purifying soluble HLA class I complexes (sHLA) from sera of melanoma patients, up to 972 high-confidence peptides could be identified, including melanoma-associated antigens already described in the literature. Knowledge of the HLA class I peptidome should facilitate multiplex tetramer technology-based characterization of T cells, and allow the development of patient selection, stratification and immunomodulatory therapeutic strategies.

Citing Articles

Soluble HLA peptidome: A new resource for cancer biomarkers.

Tanuwidjaya E, Schittenhelm R, Faridi P Front Oncol. 2023; 12:1069635.

PMID: 36620582 PMC: 9815702. DOI: 10.3389/fonc.2022.1069635.


T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles.

Hensen L, Illing P, Rowntree L, Davies J, Miller A, Tong S Front Immunol. 2022; 13:812393.

PMID: 35603215 PMC: 9121770. DOI: 10.3389/fimmu.2022.812393.


Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.

Khazan-Kost S, Cafri G, Melamed Kadosh D, Mooshayef N, Chatterji S, Dominissini D J Immunother Cancer. 2022; 10(5).

PMID: 35580925 PMC: 9114951. DOI: 10.1136/jitc-2021-003733.


ISOTOPE: ISOform-guided prediction of epiTOPEs in cancer.

Trincado J, Reixachs-Sole M, Perez-Granado J, Fugmann T, Sanz F, Yokota J PLoS Comput Biol. 2021; 17(9):e1009411.

PMID: 34529669 PMC: 8478223. DOI: 10.1371/journal.pcbi.1009411.


Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.

Qi Y, Maity T, Cultraro C, Misra V, Zhang X, Ade C Mol Cell Proteomics. 2021; 20:100136.

PMID: 34391887 PMC: 8724932. DOI: 10.1016/j.mcpro.2021.100136.


References
1.
Mohammed F, Cobbold M, Zarling A, Salim M, Barrett-Wilt G, Shabanowitz J . Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat Immunol. 2008; 9(11):1236-43. PMC: 2596764. DOI: 10.1038/ni.1660. View

2.
Michalski A, Cox J, Mann M . More than 100,000 detectable peptide species elute in single shotgun proteomics runs but the majority is inaccessible to data-dependent LC-MS/MS. J Proteome Res. 2011; 10(4):1785-93. DOI: 10.1021/pr101060v. View

3.
Hassan C, Kester M, de Ru A, Hombrink P, Drijfhout J, Nijveen H . The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics. 2013; 12(7):1829-43. PMC: 3708169. DOI: 10.1074/mcp.M112.024810. View

4.
Lu Y, Yao X, Crystal J, Li Y, El-Gamil M, Gross C . Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014; 20(13):3401-10. PMC: 4083471. DOI: 10.1158/1078-0432.CCR-14-0433. View

5.
Haen S, Rammensee H . The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials. Curr Opin Immunol. 2013; 25(2):277-83. DOI: 10.1016/j.coi.2013.03.007. View